Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter and Full Year of 2025Vehicle deliveries were 124,807 in the fourth quarter of 2025, representing an increase of 71.7% from the fourth quarter...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapiesIncreased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers SquibbFull year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554))Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5 Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted3 R&D expenses between €2.2-2.5 billion and adjusted3 SG&A expenses7 between...

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted continued commercial momentum for its bempedoic acid franchise, strong full-year revenue growth, and progress advancing its long-term strategic...

Dubai, March 10, 2026 (GLOBE NEWSWIRE) —  TransFi, a global payments infrastructure and orchestration company focused on emerging markets, today announced that it has surpassed $1 billion in processed volume on its platform, marking a significant milestone in the company’s growth. The company also said it is set to achieve $5 billion processed transaction volume in the next 12 months, based on the current pipeline and expected business conversions, reflecting growing demand from businesses seeking faster, more reliable, and more accessible cross-border payment infrastructure. TransFi now supports payments across 70+ countries and 250+ payment methods, enabling cross-border transfers on stablecoin rails with a particular focus on key emerging markets across Asia, Latin America, and the Middle East. The platform supports a range...

Key events for GEVORKYAN in 2025:Revenues grew by more than 11% YoY to over EUR 84 million EBITDA reached EUR 29 million, representing YoY growth of more than 10% EBITDA margin was over 35% Outlook for 2026-2029: Estimated annual revenue growth of 10-17%, annual EBITDA growth of 10-21%GEVORKYAN, a.s., a European leader in powder metallurgy, announces selected preliminary financial and operating results for 2025. In 2025, the company reported revenues exceeding EUR 84 million, representing a YoY increase of more than 11%. EBITDA reached EUR 29 million, representing a YoY increase of more than 10%, with an EBITDA margin of 35%. GEVORKYAN, a.s. also reported operating EBIT of EUR 10.8 million and EAT of EUR 3.9 million in 2025. Based on the results achieved, which confirmed continued revenue growth thanks to also new customer acquisitions...

Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided inaugural financial guidance for full-year 2026 Pausing GAC production and development to conduct comprehensive engineering and production process optimization review Announced leadership changes, including appointment of industry veteran as VP Operations and Finance team reorganization GREENWOOD VILLAGE, Colo., March 09, 2026 (GLOBE NEWSWIRE) — Arq, Inc. (NASDAQ: ARQ) (the “Company” or “Arq”), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial and operating results for the quarter and year ended December 31,...

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX: MHC.U; MHC.UN) today released its fourth quarter and full year 2025 results. The financial results of the REIT have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Results are shown in U.S. dollars, unless otherwise noted. Fourth Quarter 2025 ResultsCompared to Fourth Quarter 2024 ResultsRental revenue and related income was $27.5 million, an increase of 15.6% compared to $23.8 million Same Community Revenue1 was $23.2 million, up 8.2% compared to $21.4 million Net income and comprehensive income was $45.5 million...

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142’s favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial...

Not for Distribution in the United States. Failure to Comply With This Restriction May Constitute a Violation of United States Securities Law. CALGARY, Alberta, March 09, 2026 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (together, as applicable, with its subsidiaries, “Alaris” or the “Trust“) is pleased to announce its results for the three months and year ended December 31, 2025. The results are prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board. All amounts below are in Canadian dollars unless otherwise noted. HighlightsStrong Operating Growth: Total revenue and operating income increased 15.9% in Q4 and 14.0% for the year, driven primarily by a $73.2 million net unrealized gain on Partner investments (2024 – $47.3 million). Earnings from operations...

Dallas, Texas, March 09, 2026 (GLOBE NEWSWIRE) — NL Industries, Inc. (NYSE: NL) today reported a net loss attributable to NL stockholders of $31.0 million, or $.63 per share, in the fourth quarter of 2025 compared to net income attributable to NL stockholders of $16.5 million, or $.34 per share, in the fourth quarter of 2024. NL’s results include an unrealized loss of $4.5 million in the fourth quarter of 2025 compared to an unrealized loss $12.0 million in the fourth quarter of 2024 related to the change in value of marketable equity securities. For the full year of 2025, NL reported a net loss attributable to NL stockholders of $37.8 million, or $.77 per share, compared to net income attributable to NL stockholders of $67.2 million, or $1.38 per share for the full year of 2024. NL’s full year results include an unrealized loss...